Cargando…

Treatment of Active Idiopathic Inflammatory Myopathies by Low-Dose Interleukin-2: A Prospective Cohort Pilot Study

INTRODUCTION: Treatment of idiopathic inflammatory myopathies (IIMs) is challenging due to a lack of safe and efficacious medication. Low-dose interleukin-2 (IL-2) treatment emerges as a new option in active IIMs. This study aims to explore the clinical and immunological effects of low-dose IL-2 in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miao, Miao, Li, Yuhui, Huang, Bo, Chen, Jiali, Jin, Yuebo, Shao, Miao, Zhang, Xia, Sun, Xiaolin, He, Jing, Li, Zhanguo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217480/ https://www.ncbi.nlm.nih.gov/pubmed/33852146 http://dx.doi.org/10.1007/s40744-021-00301-3

Ejemplares similares

Low Dose Interleukin-2 Ameliorates Sjögren’s Syndrome in a Murine Model
por: Wang, Yifan, et al.
Publicado: (2022)

Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial
por: Zhang, Xiaoying, et al.
Publicado: (2022)

Hypomyopathic Dermatomyositis with Refractory Dermatitis Treated by Low-dose IL-2
por: Miao, Miao, et al.
Publicado: (2020)

Therapeutic potential of targeting Tfr/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study
por: Miao, Miao, et al.
Publicado: (2021)

Modification of Intestinal Microbiota Dysbiosis by Low-Dose Interleukin-2 in Dermatomyositis: A Post Hoc Analysis From a Clinical Trial Study
por: Zhufeng, Yunzhi, et al.
Publicado: (2022)

Symptomatic hyponatremia induced by low-dose cyclophosphamide in patient with systemic lupus erythematosus: A case report
por: Chen, Jiali, et al.
Publicado: (2020)

Low-Dose Interleukin-2 as an Alternative Therapy for Refractory Lupus Nephritis
por: Zhang, Xia, et al.
Publicado: (2021)

Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial
por: He, Jing, et al.
Publicado: (2022)

Low-dose IL-2 therapy invigorates CD8(+) T cells for viral control in systemic lupus erythematosus
por: Zhou, Pengcheng, et al.
Publicado: (2021)

Idiopathic inflammatory myopathy and non-coding RNA
por: Yang, Yang, et al.
Publicado: (2023)

Resistin in idiopathic inflammatory myopathies
por: Filková, Mária, et al.
Publicado: (2012)

Malignancy and Idiopathic Inflammatory Myopathies
por: Ungprasert, Patompong, et al.
Publicado: (2013)

Idiopathic inflammatory myopathies and the lung
por: Lega, Jean-Christophe, et al.
Publicado: (2015)

Retrospective analysis of low-dose interleukin-2 therapy on chronic autoimmune thyroid disease with concurrent systemic lupus erythematosus
por: Wang, Naidi, et al.
Publicado: (2023)

Tissue-Specific Autoantibodies Improve Diagnosis of Primary Sjögren's Syndrome in the Early Stage and Indicate Localized Salivary Injury
por: Jin, Yuebo, et al.
Publicado: (2019)

Monitoring change in volume of calcifications in juvenile idiopathic inflammatory myopathy: a pilot study using low dose computed tomography
por: Ibarra, Maria, et al.
Publicado: (2016)

Predictors and Mortality of Rapidly Progressive Interstitial Lung Disease in Patients With Idiopathic Inflammatory Myopathy: A Series of 474 Patients
por: Li, Yuhui, et al.
Publicado: (2020)

Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE
por: Zhou, Haotian, et al.
Publicado: (2023)

Imaging biomarkers in the idiopathic inflammatory myopathies
por: Zubair, Adeel S., et al.
Publicado: (2023)

Cardiovascular manifestations in idiopathic inflammatory myopathies
por: Shah, Meera, et al.
Publicado: (2023)

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
por: He, Jing, et al.
Publicado: (2020)

Necrotizing Autoimmune Myopathy: A Rare Variant of Idiopathic Inflammatory Myopathies
por: Khan, Noman Ahmed Jang, et al.
Publicado: (2017)

Exploring Road of Classification Criteria for Idiopathic Inflammatory Myopathy
por: Li, Yu-Hui, et al.
Publicado: (2018)

Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study
por: Lim, Johan, et al.
Publicado: (2020)

Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies
por: Grundtman, Cecilia, et al.
Publicado: (2007)

Recent advances in the immunogenetics of idiopathic inflammatory myopathy
por: Chinoy, Hector, et al.
Publicado: (2011)

Idiopathic Inflammatory Myopathies: Clinical Approach and Management
por: Malik, Asma, et al.
Publicado: (2016)

Drugs in induction and treatment of idiopathic inflammatory myopathies
por: Iaccarino, Luca, et al.
Publicado: (2014)

The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies
por: Shah, Mona, et al.
Publicado: (2013)

Idiopathic inflammatory myopathies overlapping with systemic diseases
por: Lepreux, Sébastien, et al.
Publicado: (2018)

Disease Specific Autoantibodies in Idiopathic Inflammatory Myopathies
por: Stuhlmüller, Bruno, et al.
Publicado: (2019)

Coexistence of Axial Spondyloarthritis and Idiopathic Inflammatory Myopathy
por: Ge, Yongpeng, et al.
Publicado: (2020)

MRI and muscle imaging for idiopathic inflammatory myopathies
por: Malartre, Samuel, et al.
Publicado: (2021)

Survival of Patients With Idiopathic Inflammatory Myopathies in Slovenia
por: Hočevar, Alojzija, et al.
Publicado: (2021)

Narrative review of autoantibodies in idiopathic inflammatory myopathies
por: Liu, Yilin, et al.
Publicado: (2021)

Familial autoimmunity in patients with idiopathic inflammatory myopathies
por: Che, Weng Ian, et al.
Publicado: (2022)

Predictors of cardiac involvement in idiopathic inflammatory myopathies
por: Bandeira, Matilde, et al.
Publicado: (2023)

Inflammatory lung disease a potential risk factor for onset of idiopathic inflammatory myopathies: results from a pilot study
por: Helmers, Sevim Barbasso, et al.
Publicado: (2016)

Development of the prediction model for hypertension in patients with idiopathic inflammatory myopathies
por: Qin, Li, et al.
Publicado: (2021)

Interleukin-23 as a therapeutic target for inflammatory myopathy
por: Umezawa, Natsuka, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_smavfug0d5ni0kiv329geptaos